We’re kicking off Season 3 of Tech on Drugs with Prof. Nir Hacohen — Director of the Center for Cancer Research at MGH, founding director of the Broad Institute’s Cell Circuits Program, and a distinguished member of CytoReason's Science Advisory Board.
Shai and Nir cover everything from the rise of antibodies and the promise (and pitfalls) of STING agonists, to the future of personalized cancer vaccines and a mysterious immune cell that appears only in patients with sepsis — a “cell that doesn’t exist” in healthy individuals.
This is a candid look at how deep biology, smart computation, and persistence can reshape how we treat cancer.
